Dr. Behfar Ehdaie

We enrolled those patients through the middle of COVID. So without research study assistants in the office, seeing patients virtually, without our infrastructure that we're fortunate to have at Sloan Kettering, but were not available during that trial. But the trial continued to accrue because we were still taking care of patients.

We enrolled those patients through the middle of COVID. So without research study assistants in the office, seeing patients virtually, without our infrastructure that we're fortunate to have at Sloan Kettering, but were not available during that trial. But the trial continued to accrue because we were still taking care of patients.

We enrolled those patients through the middle of COVID. So without research study assistants in the office, seeing patients virtually, without our infrastructure that we're fortunate to have at Sloan Kettering, but were not available during that trial. But the trial continued to accrue because we were still taking care of patients.

And so that was another pearl that by decluttering the clinical trial process, making it more part of what we do in an integrated fashion, we can enroll more patients, we get more patients access to trials and answer questions that are not deemed landmark questions, but important questions because the cost or incremental cost is very low to our healthcare system, including our resources.

And so that was another pearl that by decluttering the clinical trial process, making it more part of what we do in an integrated fashion, we can enroll more patients, we get more patients access to trials and answer questions that are not deemed landmark questions, but important questions because the cost or incremental cost is very low to our healthcare system, including our resources.

And so that was another pearl that by decluttering the clinical trial process, making it more part of what we do in an integrated fashion, we can enroll more patients, we get more patients access to trials and answer questions that are not deemed landmark questions, but important questions because the cost or incremental cost is very low to our healthcare system, including our resources.

And to your point, A lot of what we do is based on what has been done in the past. So we just follow that same model.

And to your point, A lot of what we do is based on what has been done in the past. So we just follow that same model.

And to your point, A lot of what we do is based on what has been done in the past. So we just follow that same model.

The other aspect, and I'll throw another pearl, is that I really think joining research council committees, IRB committees in your hospital will open your eyes to not only see sort of the breadth of research being done in the institution, but how clinical trials are being scrutinized. I sat on the Research Council here at Memorial for five years.

The other aspect, and I'll throw another pearl, is that I really think joining research council committees, IRB committees in your hospital will open your eyes to not only see sort of the breadth of research being done in the institution, but how clinical trials are being scrutinized. I sat on the Research Council here at Memorial for five years.

The other aspect, and I'll throw another pearl, is that I really think joining research council committees, IRB committees in your hospital will open your eyes to not only see sort of the breadth of research being done in the institution, but how clinical trials are being scrutinized. I sat on the Research Council here at Memorial for five years.

The most we would scrutinize is eligibility and exclusionary criteria as part of a trial. And that would be a reason a trial would go back and forth with the investigator, give edits, come back to the Research Council, give edits, go back. And then we prolonged approval for three to six months just talking about liver function tests.

The most we would scrutinize is eligibility and exclusionary criteria as part of a trial. And that would be a reason a trial would go back and forth with the investigator, give edits, come back to the Research Council, give edits, go back. And then we prolonged approval for three to six months just talking about liver function tests.

The most we would scrutinize is eligibility and exclusionary criteria as part of a trial. And that would be a reason a trial would go back and forth with the investigator, give edits, come back to the Research Council, give edits, go back. And then we prolonged approval for three to six months just talking about liver function tests.

Part of what we do in clinical and creative trials is actually to eliminate almost all eligibility criteria and exclusionary criteria. Typically now, when I write a trial, I want one or two lines of eligibility and exclusionary criteria because what we're trying to answer is patients that we are treating now. So the eligibility is a patient that I'm already treating.

Part of what we do in clinical and creative trials is actually to eliminate almost all eligibility criteria and exclusionary criteria. Typically now, when I write a trial, I want one or two lines of eligibility and exclusionary criteria because what we're trying to answer is patients that we are treating now. So the eligibility is a patient that I'm already treating.

Part of what we do in clinical and creative trials is actually to eliminate almost all eligibility criteria and exclusionary criteria. Typically now, when I write a trial, I want one or two lines of eligibility and exclusionary criteria because what we're trying to answer is patients that we are treating now. So the eligibility is a patient that I'm already treating.

I've already determined eligibility. And so everything gets scrutinized. Everything that's an exclusionary eligibility criteria, remember, a research study system has to sit there with a checkbox. with every patient and make sure those things don't fit in those criteria. So we've now really emphasized, eliminate things that are not necessary.

I've already determined eligibility. And so everything gets scrutinized. Everything that's an exclusionary eligibility criteria, remember, a research study system has to sit there with a checkbox. with every patient and make sure those things don't fit in those criteria. So we've now really emphasized, eliminate things that are not necessary.